Beam Therapeutics BEAM Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $288.29M-2.3% | $294.94M+10.1% | $267.96M-5.0% | $282.13M-46.6% | $527.91M+87.2% | ||
| $923.36M-2.8% | $950.27M+17.8% | $807.01M-7.0% | $868.21M+25.5% | $692.05M+21.7% | ||
| $1.27B-0.1% | $1.27B+15.5% | $1.1B-6.5% | $1.18B-5.8% | $1.25B+42.1% | ||
| $101.25M-3.1% | $104.5M-3.5% | $108.29M-0.5% | $108.82M-0.7% | $109.57M-1.7% | ||
| $1.48B0.0% | $1.48B+13.0% | $1.31B-5.8% | $1.39B-5.2% | $1.47B+32.9% | ||
| $42.62M+12.1% | $38.03M+20.1% | $31.67M+22.1% | $25.94M+30.9% | $19.81M+32.9% | ||
| $304K-95.4% | $6.66M-94.0% | $110.32M+4.3% | $105.82M+24.2% | $85.2M-21.7% | ||
| $74.57M-23.1% | $96.94M-46.9% | $182.56M+4.8% | $174.13M+23.0% | $141.55M-22.3% | ||
| —— | —— | —— | —— | —— | ||
| $316.36M+30.3% | $242.82M-29.6% | $345.08M+0.2% | $344.34M+0.2% | $343.78M-7.2% | ||
| $1.03M+1.0% | $1.02M+0.3% | $1.01M+0.6% | $1.01M+0.2% | $1.01M+20.3% | ||
| -$1.74B-5.7% | -$1.64B+13.2% | -$1.89B-6.3% | -$1.78B-6.1% | -$1.68B-7.0% | ||
| $1.16B-6.0% | $1.24B+28.2% | $966M-7.7% | $1.05B-7.3% | $1.13B+54.0% | ||
| $1.48B0.0% | $1.48B+13.0% | $1.31B-5.8% | $1.39B-5.2% | $1.47B+32.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Beam Therapeutics cover its short-term obligations?
- Its current ratio is 16.99 — current assets exceed current liabilities.
- Where does Beam Therapeutics's balance sheet data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.